TY  - GEN 
AU  - Camidge, D Ross
AU  - Kim, Hye Ryun
AU  - Ahn, Myung-Ju
AU  - Yang, James C H
AU  - Han, Ji-Youn
AU  - Hochmair, Maximilian J
AU  - Lee, Ki Hyeong
AU  - Delmonte, Angelo
AU  - García Campelo, María del Rosario
AU  - Kim, Dong-Wan
AU  - Griesinger, Frank
AU  - Felip, Enriqueta
AU  - Califano, Raffaele
AU  - Spira, Alexander
AU  - Gettinger, Scott N
AU  - Tiseo, Marcello
AU  - Lin, Huamao M
AU  - Gupta, Neeraj
AU  - Hanley, Michael J
AU  - Ni, Quanhong
AU  - Zhang, Pingkuan
AU  - Popat, Sanjay
PY  - 2020
SN  - 0732-183X
UR  - http://hdl.handle.net/20.500.11940/16284
AB  - PURPOSE: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor-naive ALK-positive...
KW  - Adult
KW  - Carcinoma
KW  - Organophosphorus Compounds
KW  - Middle Aged
KW  - Adolescent
KW  - Quality of Life
KW  - Survival Rate
KW  - Antineoplastic Agents
KW  - Lung Neoplasms
KW  - Pyrimidines
KW  - Humans
KW  - Young Adult
KW  - Aged
TI  - Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
DO  - 10.1200/JCO.20.00505
KW  - CHUAC
VL  - 38
ER  -